We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us

Destiny Pharma Holdings plc (DEST) Ord GBP0.01

Sell:39.00p Buy:41.00p 0 Change: No change
Market closed |  Prices as at close on 11 August 2022 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:39.00p
Buy:41.00p
Change: No change
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 11 August 2022 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:39.00p
Buy:41.00p
Change: No change
Market closed |  Prices as at close on 11 August 2022 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Destiny Pharma plc is a clinical stage, biotechnology company. The Company is engaged in the discovery, development, and commercialization of novel medicines with a focus on infection prevention. It is focused on developing novel antimicrobial drug from its exeporfinium chloride platform and also from two biotherapeutic products. Its pipeline includes XF-73 nasal gel, NTCD-M3, and XF-73 dermal. XF-73 nasal gel is developed for the prevention of post-surgical staphylococcal infections. NTCD-M3, which is a naturally occurring non-toxigenic strain of C. difficile which lacks the genes that can express C. difficile toxins. NTCD-M3 is used for the prevention of C. difficile infection (CDI) recurrence. XF-73 derma is developed for the prevention and treatment of serious infections associated with wounds and ulcers such as diabetic foot ulcers (DFUs). The Company is co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections.

Contact details

Address:
Sussex Innovation Centre
Science Park Square, Falmer
BRIGHTON
BN1 9SB
United Kingdom
Telephone:
+44 (01273) 704440
Website:
https://www.destinypharma.com/

Important dates

Future events
There are no future events available.
Past events
AGM 27 May 2022 27/05/22
Annual report 27 April 2022 27/04/22
Final results 12 April 2022 12/04/22
Interim results 09 September 2021 09/09/21

General stock information

EPIC:
DEST
ISIN:
GB00BDHSP575
Market cap:
£29.32 million
Shares in issue:
73.31 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Neil Clark
    Chief Executive Officer, Executive Director
  • William Love
    Founder, Chief Scientific Officer, Executive Director
  • Shaun Claydon
    Chief Financial Officer, Executive Director, Company Secretary
  • Stephanie Bewick
    Chief Business Officer
  • Yuri Martina
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.